Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory and reversible airway obstruction seen in asthma with the progressive airflow limitation characteristic of COPD.

The symptoms of COPD can vary, but they often include persistent coughs, breathlessness, increased production of sputum, and intermittent exacerbations or flare-ups of severe symptoms that impact the quality of life for individuals with COPD.

Managing COPD involves a combination of medication and lifestyle changes. Bronchodilators, such as ipratropium bromide (an anticholinergic agent) and albuterol (a β₂-adrenergic agonist), form the backbone of COPD treatment. They relax the muscles around the airways in the lungs, reducing respiratory symptoms and improving lung function. They are typically administered through inhalers or nebulizers, with longer-acting forms requiring less frequent dosing.

While systemically active glucocorticoids, or corticosteroids, have demonstrated limited efficacy in treating COPD, inhaled corticosteroids can improve patients' quality of life. However, it's important to note that these do not halt the decline in lung function that characterizes this disease.

Theophylline (Theolair), a type of bronchodilator, can be particularly beneficial for patients who retain CO₂. It relaxes and opens the airways to the lungs, making breathing easier. It can also improve ventilatory capacity by enhancing the contractile function of the diaphragm. However, its use is limited by narrow therapeutic margins and the potential for side effects such as nausea, insomnia, and arrhythmias.

Antibiotics are another essential component of COPD management. They are typically used to treat COPD exacerbations due to lower airway bacterial infections, reducing the duration and severity of these episodes.

For patients with severe COPD and chronic hypoxemia, long-term oxygen therapy (LTOT) may be recommended. LTOT can help to reduce the symptoms of breathlessness and fatigue, improve sleep and mood, increase mobility, and, in some cases, extend life expectancy.

Lifestyle modifications are essential for COPD management. Most importantly, smoking cessation and avoiding smoke exposure are vital, as smoking is a significant risk factor for developing and exacerbating COPD. Regular physical activity, a balanced diet, and avoiding respiratory irritants can also contribute to better disease management and quality of life.